Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 5Unknown 2Recruiting 2Completed 2Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 20Lung Neoplasms 6Small Cell Lung Carcinoma 4Ovarian Neoplasms 4Neoplasms 4Colorectal Neoplasms 4Uterine Cervical Neoplasms 3Urinary Bladder Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Recurrence 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Multiple Myeloma 3Lymphoma, Large B-Cell, Diffuse 3Breast Neoplasms 3Vulvar Neoplasms 2Vaginal Neoplasms 2Triple Negative Breast Neoplasms 2Prostatic Neoplasms 2Lymphoma, Non-Hodgkin 2Head and Neck Neoplasms 2Cholangiocarcinoma 2Carcinoma, Transitional Cell 2Carcinoma, Hepatocellular 2Urothelial Cancer 1Urinary Bladder Diseases 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Thrombocytosis 1Testicular Neoplasms 1

Interventions

pembrolizumab 8Paclitaxel 8Carboplatin 6Megestrol Acetate 4niraparib 3Cisplatin 3tislelizumab 2technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 2rucaparib 2olaparib 2iso-sulfan blue 2copanlisib 2Taxes 2Surveys and Questionnaires 2Nivolumab 2Lymph Node Excision 2Indocyanine Green 2Fulvestrant 2Filgrastim 2Doxorubicin 2Docetaxel 2tremelimumab 1spartalizumab 1sonidegib 1ribociclib 1rebastinib 1pemigatinib 1nicotinamide-beta-riboside 1lenvatinib 1ixabepilone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Endometrial Neoplasms × durvalumab × Clear all
NCT03277482 2025-05-31

Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer

Dana-Farber Cancer Institute

Phase 1 Terminated
16 enrolled
Gynecologic

Uterine Cervical Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡